AXIM Biotechnologies (AXIM) Stock Price, News & Analysis

Company Overview

AXIM Biotechnologies, Inc. is a development-stage biotechnology company focused on the research, development and commercialization of cannabinoid-based technologies. The company’s primary objective is to advance formulations and delivery systems for cannabidiol (CBD) and other cannabinoids, targeting applications in nutraceuticals, skincare and medical devices. Through its proprietary encapsulation and atomization techniques, AXIM aims to enhance the bioavailability and stability of cannabinoid compounds for consumer and clinical use.

The company’s product pipeline includes novel CBD-infused nutraceuticals designed to promote general wellness, as well as specialized formulations for topical and inhalation delivery. AXIM holds a portfolio of patents and patent applications covering methods of producing microand nano-emulsions, sustained-release capsules, and rapid-dissolve strips. In addition to internal research activities, the company collaborates with academic laboratories and contract research organizations to validate safety profiles and therapeutic potential of its lead candidates.

Headquartered in New York, AXIM Biotechnologies serves the U.S. market through direct-to-consumer channels and partnerships with regional distributors. The company is also exploring opportunities in Latin America and Europe, where regulatory frameworks for medical cannabis and CBD products are evolving. Governance is overseen by a board of directors and experienced management team with backgrounds in biopharmaceutical development, regulatory affairs and product commercialization. AXIM continues to refine its business strategy as it progresses toward regulatory approvals and commercial launches of its advanced cannabinoid platforms.

Key Stats

• Today's Range: $0.0045 to $0.0046
• 50-Day Range: $0.0044 to $0.0078
• 52-Week Range: $0.0013 to $0.0098
• Volume: 33,711 shs
• Average Volume: 278,662 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AXIM Stock Analysis - Frequently Asked Questions

How have AXIM shares performed this year?

AXIM Biotechnologies' stock was trading at $0.0019 at the start of the year. Since then, AXIM stock has increased by 136.8% and is now trading at $0.0045.

How do I buy shares of AXIM Biotechnologies?

Shares of AXIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AXIM Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AXIM Biotechnologies investors own include Cronos Group (CRON), Canopy Growth (CGC), Tilray Brands (TLRY), Charlotte's Web (CWBHF), Baidu (BIDU), Meta Platforms (META) and Micron Technology (MU).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AXIM
• CIK: 1514946
• Web: aximbiotech.com
• Phone: (858) 923-4422
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A